电邮这篇文章 Diroton effects on 24-h fluctuations of arterial pressure as shown bymonitoring in hypertensive patients with polycythemia vera
- 作者: Gorokhovskaya GN1, Zavyalova AI1, Martynov AI1
-
隶属关系:
- Московский государственный медико-стоматологический университет
- 期: 卷 78, 编号 8 (2003)
- 页面: 26-32
- 栏目: Editorial
- URL: https://journal-vniispk.ru/0040-3660/article/view/33354
- ID: 33354
如何引用文章
全文:
详细
Aim. To study the data of 24-h monitoring of blood pressure (MBP) and effects of an ACE inhibitor
lisinopril (diroton) in hypertensive patients with polycythemia vera (PV).
Material and methods. 20 patients with arterial hypertention of degree II and III with PV aged 41 to
77 years. Mean duration of AH and PV was 11.8 ± 2.2 and 2.0 ± 0.2 years, respectively. Diroton
was given as monotherapy in a single morning dose 10-40 mgfor 4 weeks. 24-h MBP was made before
the treatment and on the 4th week of the treatment. In addition to standard estimations, hour-tohour
double product (DP) was estimated.
Results. After 4 weeks of diroton therapy there was a 12.2%, 9.5%, 25% and 15.4% fall in mean 24-h systolic
blood pressure (SBP), diastolic blood pressure (DBP), pulse pressure (PP), DP, respectively.
A positive effect was registered on variability and 24-h profile of BP. A response was achieved in 85%
patients. The target level of mean 24-h blood pressure < 135/85 mm Hg was achieved in 65%, and
10% fall in SBD and/or &BP in 20% patients. ACE inhibitors' side effect - severe dry cough - was
not encountered.
Conclusion. PV aggravates arterial hypertention. Monotherapy with diroton effectively controls BP in
hypertensive patients with PV in a 4-week course intake in a single morning dose and is well tolerated
lisinopril (diroton) in hypertensive patients with polycythemia vera (PV).
Material and methods. 20 patients with arterial hypertention of degree II and III with PV aged 41 to
77 years. Mean duration of AH and PV was 11.8 ± 2.2 and 2.0 ± 0.2 years, respectively. Diroton
was given as monotherapy in a single morning dose 10-40 mgfor 4 weeks. 24-h MBP was made before
the treatment and on the 4th week of the treatment. In addition to standard estimations, hour-tohour
double product (DP) was estimated.
Results. After 4 weeks of diroton therapy there was a 12.2%, 9.5%, 25% and 15.4% fall in mean 24-h systolic
blood pressure (SBP), diastolic blood pressure (DBP), pulse pressure (PP), DP, respectively.
A positive effect was registered on variability and 24-h profile of BP. A response was achieved in 85%
patients. The target level of mean 24-h blood pressure < 135/85 mm Hg was achieved in 65%, and
10% fall in SBD and/or &BP in 20% patients. ACE inhibitors' side effect - severe dry cough - was
not encountered.
Conclusion. PV aggravates arterial hypertention. Monotherapy with diroton effectively controls BP in
hypertensive patients with PV in a 4-week course intake in a single morning dose and is well tolerated
作者简介
G Gorokhovskaya
Московский государственный медико-стоматологический университетМосковский государственный медико-стоматологический университет
A Zavyalova
Московский государственный медико-стоматологический университетМосковский государственный медико-стоматологический университет
A Martynov
Московский государственный медико-стоматологический университетМосковский государственный медико-стоматологический университет
参考
- Арабидзе Г. Г., Белоусов Ю. Б., Карпов Ю. А. Артериальная гипертония. М.; 1999. 61-65.
- Кобалава Ж. Д., Котовская Ю. В. Артериальная гипертония 2000. М.;2001. 14-117.
- Grobbecker H., Heusch G., Strauer В. Е. Angiotensin and the heart. 1993; 88(suppl. 1).
- Маколкин В. И., Подзолков В. И. Гипертоническая болезнь. М.; 2000. 65-69.
- Алмазов В. А., Шляхто Е. В. Кардиология для врача общей практики. Т. 1: Гипертоническая болезнь. СПб: Изд-во СПбГМУ: 2001. 104-107.
- Azizi M., Ezan E., Nicolet L., Grodnet J. M. High plasma level of N-acetyl-seryl-asparty-lysyl-prolin. A new marker of chronic angiotensin-converting enzyme inhibition. Hypertension 1997; 30(5): 1015-1019.
- Ольбинская Л. И. Артериальные гипертензии. М.: Медицина; 1998. 163-191.
- Агеев Ф. Т., Константинова Е. В., Овчинников А. Г. Ингибиторы АПФ - краеугольный камень в лечении сердечной недостаточности. Рус. мед. журн. 1999; 2: 70-75.
- Bearden D., Allman R., McDonald R. Systolic hypertension in the elderly program. J. Am. Geriatr. Soc. 1994; 42: 1143- 1149.
- Borghi C., Ambrosioni E. Evidence based medicine and ACE inhibition. J. Cardiovasc. Pharmacol. 1998; 32(suppl. 2): 24-35.
- Метелица В. И. Справочник по клинической фармакологии сердечно-сосудистых лекарственных средств. М.: Медпрактика; 1996. 272-293.
- Баркаган З. С., Момот А. П. Диагностика и контролируемая терапия нарушений гемостаза. М.; 2001. 32-38.
- Сидоренко Б. А., Преображенский Д. В. Ингибиторы ангиотензинпревращающего фермента. М.; 1999. 8-71.
- Кукес В. Г., Теплоногова Е. В. Ингибиторы АПФ в кардиологии: место трандолаприла. Клин, фармакол. и тер. 1999; 8(3): 53-58.
- Преображенский Д. В., Сидоренко Б. А., Романова Н. Е.,Шатунова И. М. Клиническая фармакология основных классов антигипертензивных препаратов. Consilium Medicum 2000; 2(3): 117.
- Repine C. Systemic hypertension and coronary artery disease.Am. J. Cardiol. 1998; 82: 21-24.
- Cheng A., Frishman W. Use of angiotensin-converting enzyme inhibitors as monotherapy and combination with diuretics and calcium channel blockers. J. Clin. Pharmacol. 1998; 38(6): 477-491.
- White C. Pharmacologic, pharmacokinetic and therapeutic differences among ACE inhibitors. Pharmacotherapy 1998; 18(3): 588-599.
- Madhaven S., Ooi W. L., Cohen Н., Alderman M. H. Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension 1994; 23: 395-401.
- Frohlich E. D. Пульсовое давление - прогностически значимый фактор риска при артериальной гипертензии. Современные подходы в лечении артериальной гипертензии № 2. Медицинское издание фармацевтической группы Сервье. Новый Орлеан, 2000.
- Комаров Ф. И., Ольбинская Л. И., Хапаев Б. А. Циркадианный ритм гемодинамической нагрузки на сердечно-сосудистую систему у больных эссенциальной артериальной гипертензией - значение для рациональной фармакотерапии. Клин. мед. 2001; 3: 52-55.
补充文件
